EMA
- Application: EMEA/H/C/002140
- Local brand name: Sumatriptan Galpharm
- Status: refused
Imitrex (SUMATRIPTAN) regulatory status in European Union.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. EMA has authorised it.
GSK is the originator. The local marketing authorisation holder may differ — check the official source linked above.